The Shortage Is Over — But the Access Problem Isn't
In February 2025, the FDA officially removed semaglutide from its drug shortage database. On paper, that sounds like a win. In practice, thousands of patients who had been receiving compounded semaglutide — legally, affordably, and often more consistently than the branded versions — woke up to a ticking clock on their supply chain.
If you've been running a wellness or weight loss practice, you already felt this. Patients who had stabilized on compounded doses started calling. Compounding pharmacies started sending compliance notices. And the branded alternatives — Ozempic at ~$900/month and Wegovy at ~$1,300/month out of pocket — were suddenly the only FDA-endorsed path forward for most people. That math doesn't work for the majority of patients who relied on compounding because it was the only financially viable option.
This article breaks down exactly what the 2025 FDA shortage transition means for compounded semaglutide pharmacy access, what the compliance deadlines look like, and what clinicians and informed patients should be doing right now.
What the FDA Shortage Removal Actually Triggered
Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to produce copies of commercially available drugs only when those drugs appear on the FDA's official shortage list. The moment semaglutide was delisted, that legal basis — for most standard compounding operations — evaporated.
The FDA drew a hard line with two distinct deadlines:
- 503A pharmacies (patient-specific, prescription-based compounders): Given until April 22, 2025 to wind down compounded semaglutide production.
- 503B outsourcing facilities (larger-scale, bulk compounders): Given until May 22, 2025 to cease production.
These weren't suggestions. FDA enforcement discretion formally ended at those dates. Pharmacies continuing to produce after those deadlines risked Warning Letters, injunctions, and seizure actions. Some had already received informal notices before the deadlines passed.
The narrow exception: compounders can still legally produce semaglutide if a patient has a documented, clinically significant difference in need — for example, a specific dose not available commercially, or a documented allergy to an excipient in the branded product. This is a real pathway, but it requires specific prescriber documentation and isn't a blanket workaround.
The 503A vs. 503B Distinction Matters More Than Ever
Most patients and even many clinicians conflate 503A and 503B pharmacies. The distinction became critically important the moment the shortage ended.
503A pharmacies compound medications for individual patients based on valid prescriptions. They operate under state pharmacy board oversight primarily. They cannot produce in bulk or sell to practitioners for office use. Their semaglutide compounding window closed first — April 22, 2025.
503B outsourcing facilities are FDA-registered, can produce larger batches, and can sell to healthcare facilities without patient-specific prescriptions. They face stricter federal cGMP (current Good Manufacturing Practice) standards. Their deadline was May 22, 2025, giving them an extra 30 days — but that window is also now closed for standard formulations.
What this means operationally: if your practice was sourcing compounded semaglutide from a 503B facility and received an inventory shipment in May, that inventory was produced under a deadline. Once it's gone, it's gone — unless the compounder qualifies under one of the narrow exemptions. Understanding how to properly store and handle peptide compounds becomes even more critical when supply is constrained and waste is not an option.
The Salt Formulation Controversy: Acetate and Sodium Forms
One of the more contentious technical debates in this transition involves which form of semaglutide compounders were using. Novo Nordisk's branded products use semaglutide base. Many compounders were using semaglutide acetate or semaglutide sodium — salt forms not identical to the reference listed drug.
The FDA's position, communicated through a March 2025 guidance update, is that these salt forms are not the same active ingredient as the FDA-approved semaglutide base. That framing gives the agency a strong enforcement argument: compounders using acetate or sodium salts were arguably never legally compounding a copy of an FDA-approved drug — they were producing an unapproved new drug.
Several 503B facilities pushed back, arguing the biological activity is equivalent and the distinction is regulatory semantics. The FDA hasn't budged. For clinicians advising patients, this salt form issue is worth understanding — it affects both the legal standing of previous supplies and the risk profile of any remaining inventory sourced before the deadline.
This debate also connects to broader questions about how GLP-1 receptor agonists work at the molecular level, since even small structural differences in peptide formulations can affect receptor binding kinetics and bioavailability — not just regulatory classification.
What Legitimate Pathways Still Exist Post-Deadline
Despite the regulatory tightening, there are still legally defensible options. They require more documentation and clinical specificity, but they exist.
1. Documented clinical need for a different dose or formulation. If a patient requires a dose not commercially available — for example, a 0.5mg weekly titration not offered by Wegovy or Ozempic — a compounding pharmacy can argue legitimate clinical differentiation. This requires written prescriber justification, and the burden of proof sits with the prescriber and the pharmacy, not the patient.
2. Allergy or excipient sensitivity. The branded semaglutide products contain specific excipients (including disodium phosphate dihydrate, propylene glycol, and others). If a patient has a documented sensitivity to any of these, compounding a version without that excipient may qualify. This needs to be in the medical record — not inferred.
3. Tirzepatide as an alternative. As of mid-2025, tirzepatide remains on the FDA shortage list. That means compounded tirzepatide — which targets both GLP-1 and GIP receptors — is still a legally available option through 503A and 503B pharmacies. For many patients who were on semaglutide, clinicians are already evaluating a transition. Understanding the clinical differences between semaglutide and tirzepatide is essential before making that recommendation.
4. Manufacturer patient assistance programs. Novo Nordisk's patient assistance programs have expanded in response to the access crisis. Patients under a specific income threshold may qualify for Wegovy or Ozempic at significantly reduced or no cost. These programs are underutilized because the application process is tedious — but they are real, and clinicians should have a staff workflow for identifying eligible patients.
Enforcement Reality: What's Actually Happening on the Ground
Federal policy and enforcement reality are not always the same thing — especially in the first months after a rule change. Here's what practitioners are actually reporting as of mid-2025:
- Several large 503B facilities ceased semaglutide production voluntarily before or at the deadline, citing legal risk.
- Some smaller 503A pharmacies are still filling semaglutide prescriptions, citing the clinical differentiation exemption — with varying levels of documentation rigor.
- The FDA has issued Warning Letters to at least two facilities (publicly available on FDA.gov) for continuing to produce compounded semaglutide after the deadline without qualifying exemption documentation.
- State pharmacy boards have been uneven in their enforcement responses — some states with strong compounding industries have been slower to act.
For clinicians, the practical risk isn't just regulatory — it's liability. Prescribing from a pharmacy that is operating outside of its legal authorization transfers some of that risk to the prescriber. If a patient has an adverse event and the medication was sourced from a non-compliant compounder, that's a malpractice exposure scenario worth taking seriously.
The FDA maintains a public list of 503B outsourcing facilities in good standing at FDA.gov's registered outsourcing facilities database. Cross-referencing your pharmacy partners against that list is a basic due diligence step that takes five minutes.
How to Transition Patients Without Losing Them
The clinical and business challenge running simultaneously here is real: patients who were stable on compounded semaglutide are anxious, and some are considering stopping treatment altogether because they can't afford the branded alternative. A practice that loses 30–40 GLP-1 patients in a single quarter because of a formulary disruption feels that in revenue and outcomes data.
Here's a protocol that has worked in practice:
Step 1 — Audit your current patient panel immediately. Identify every patient on compounded semaglutide. Flag those approaching dose transitions (moving from 0.5mg to 1mg, for example) because those are the highest risk for dropout when supply disrupts.
Step 2 — Segment by financial eligibility. Run a quick income screen. Patients at or below 400% of the federal poverty level likely qualify for Novo Nordisk assistance programs. Patients with commercial insurance should have coverage pathways evaluated — many plans cover Wegovy with prior authorization for BMI ≥30 or ≥27 with comorbidities.
Step 3 — Evaluate tirzepatide candidacy. For patients who are not progressing optimally on semaglutide or who have plateaued in weight loss, this transition moment is actually a clinical opportunity. Tirzepatide's dual-agonist mechanism produces meaningfully different outcomes for certain patient profiles. Review your lab data before making this call — not all patients are interchangeable.
Step 4 — Document clinical differentiation if compounding is still warranted. If you have a genuine clinical basis for continued compounding, build the paper trail now. Write the clinical note, specify the medical necessity, and confirm the pharmacy has its own legal review in place. Don't rely on verbal assurances from your compounding partner about their compliance status.
For practices looking at the broader peptide therapy landscape during this transition, understanding the emerging role of GLP-3 and next-generation peptide compounds in metabolic management is worth including in your clinical education pipeline.
What to Expect in the Next 6–12 Months
The policy environment around compounded semaglutide will continue to evolve. Several dynamics are worth tracking:
- Congressional pressure: Multiple bills have been introduced in 2025 addressing drug pricing and compounding access. None have passed as of this writing, but the political pressure on Novo Nordisk to reduce pricing is real and sustained.
- Biosimilar pipeline: The first semaglutide biosimilar approvals are anticipated in 2026. Once biosimilars enter the market, branded pricing typically drops 20–40% within 12–18 months. That changes the access equation significantly.
- FDA guidance clarification: The agency has signaled it will release additional clarifying guidance on the clinical differentiation exemption — specifically, what documentation standard it expects from prescribers. When that drops, it will either open or close the compounding window further.
- State-level legislation: Several states, including Florida and Texas, have introduced legislation that would create state-level pathways for compounded GLP-1 access independent of federal shortage status. These are legally complex and may face federal preemption challenges, but they're moving.
The FDA's compounding Q&A page is updated regularly and should be part of any practice's compliance monitoring routine.
The Bottom Line for Clinicians and Patients Right Now
The 2025 FDA shortage transition for compounded semaglutide is not a temporary inconvenience — it's a structural policy shift that requires a structural response. Practices that treat it as a short-term supply disruption will find themselves making reactive decisions repeatedly. Practices that audit their patient panels, establish compliant pharmacy partnerships, and build financial access workflows now will be better positioned regardless of how the policy landscape shifts over the next year.
The patients most at risk are those who were stable, making progress, and now face a coverage or affordability gap. That's a clinical failure if we allow administrative and policy friction to drive them off treatment.
Your action step this week: Pull your compounded semaglutide patient list. Verify your pharmacy partner's 503B registration status on the FDA database. Schedule 15 minutes with your billing team to map out which patients have insurance coverage pathways for Wegovy, and identify who needs a tirzepatide conversation or a patient assistance referral. That single audit will tell you everything you need to know about your exposure — and your opportunity.